EAGLE PHARMACEUTICALS, INC.【EGRX】
| Sep 30,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Net income (loss) | -18 | 3 | 81 | 52 | 32 | 14 | 12 | -9 | 36 |
|---|
| Deferred income taxes | - | - | -30 | 17 | -2 | 0 | -2 | -4 | -8 |
|---|
| Depreciation | 0 | - | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
|---|
| Operating Lease, Right-of-Use Asset, Amortization Expense | - | - | - | - | - | - | 1 | 1 | 1 |
|---|
| Amortization of Intangible Assets | - | - | 1 | 3 | 3 | 3 | 3 | 3 | 11 |
|---|
| Stock-based compensation expense | 1 | 4 | 10 | 15 | 19 | 22 | 25 | 20 | 16 |
|---|
| Fair value adjustments on equity investment | - | - | - | - | - | - | -5 | -6 | -4 |
|---|
| Amortization of debt issuance costs | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Fair Value Adjustment On Accelerated Share Repurchases | - | - | - | - | - | - | 3 | - | - |
|---|
| Fair value adjustments related to derivative instrument | - | - | - | - | - | - | - | 1 | -1 |
|---|
| Gain on fair value adjustments related to debt | - | - | - | - | - | - | - | - | 0 |
|---|
| Accretion of discount on convertible promissory note | - | - | - | - | - | - | - | 0 | - |
|---|
| Loss on write-off of promissory note | - | - | - | - | - | - | - | - | -4 |
|---|
| Accounts receivable | 2 | 14 | 16 | 12 | 13 | -18 | 3 | -10 | 31 |
|---|
| Inventories | 1 | 14 | -12 | 2 | 6 | -2 | 2 | 14 | 8 |
|---|
| Prepaid expenses and other current assets | -0 | 0 | 9 | -2 | -5 | 5 | -11 | 3 | 5 |
|---|
| Accounts payable | 3 | 0 | 11 | -8 | -2 | -4 | 1 | 10 | 3 |
|---|
| Accrued expenses and other liabilities | 7 | 12 | -0 | -9 | 8 | 4 | -4 | 8 | 44 |
|---|
| Other assets and other long-term liabilities, net | - | - | - | - | - | - | - | - | 19 |
|---|
| Net cash provided by operating activities | -14 | -10 | 53 | 59 | 52 | 56 | 49 | 28 | 51 |
|---|
| Purchase of Acacia, net of cash acquired | - | - | 27 | - | - | - | - | - | 74 |
|---|
| Purchase of equity investment security | - | - | - | - | - | - | - | - | 13 |
|---|
| Purchase of property and equipment | 0 | 2 | 2 | 4 | 0 | 1 | 1 | 0 | 0 |
|---|
| Net cash used in investing activities | -20 | -2 | -46 | -5 | -0 | -1 | -18 | -5 | -87 |
|---|
| Repurchases of common stock | - | - | 37 | 44 | 73 | 18 | 35 | 21 | 18 |
|---|
| Proceeds from Issuance of Debt | - | - | - | 50 | - | - | 110 | - | 30 |
|---|
| Repayment of existing revolving credit facility | - | - | - | - | - | - | 110 | - | 15 |
|---|
| Debt proceeds | - | - | - | - | - | - | - | - | 50 |
|---|
| Payment of debt | - | - | - | 1 | 4 | 6 | 5 | 8 | 52 |
|---|
| Payment of debt financing costs | - | - | - | 1 | - | 0 | - | - | 1 |
|---|
| Payment of employee withholding tax upon vesting of stock-based awards | - | - | - | - | 5 | 0 | 2 | 2 | 1 |
|---|
| Proceeds from Stock Options Exercised | 0 | 1 | 4 | 4 | 9 | 0 | 4 | 2 | 2 |
|---|
| Net cash used in financing activities | 46 | 56 | -34 | 8 | -88 | -24 | -38 | -28 | -6 |
|---|
| Net decrease in cash and cash equivalents | - | - | - | - | - | 31 | -7 | -5 | -42 |
|---|
| Income taxes, net | - | 0 | 3 | 11 | 2 | 7 | 6 | 10 | 28 |
|---|
| Interest | - | - | - | - | - | 2 | 2 | 1 | 2 |
|---|
| Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | - | - | - | - | - | 4 | 1 | 0 | - |
|---|